Anandamide
|
Basic information |
| Metabolite name | Anandamide |
 | HMDB0004080 |
 |
C11695 |
 |
5281969 |
| Synonyms | N-arachidonoylethanolamine; |
| No. of studies | 32 |
|
Basic information |
| Metabolite name | Anandamide |
| HMDB0004080 |
|
C11695 |
|
5281969 |
| Synonyms | N-arachidonoylethanolamine; |
| No. of studies | 32 |
|
Relationship between Anandamide and depression (count: 32) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1120 | Type1 | depressive group vs. control group | Hair | Human | Down |
| Study M1128 | Type3 | arachidonyl serotonin group vs. control group | Prefrontal cortex | CD1 mouse | Up |
| Study M1128 | Type3 | biochanin-A group vs. control group | Prefrontal cortex | CD1 mouse | Up |
| Study M1128 | Type3 | 7-hydroxyflavone group vs. control group | Prefrontal cortex | CD1 mouse | Up |
| Study M1128 | Type3 | genistein group vs. control group | Prefrontal cortex | CD1 mouse | Up |
| Study M1128 | Type3 | fluoxetine group vs. control group | Prefrontal cortex | CD1 mouse | Up |
| Study M160 | Type1 | CUMS group vs. control group | Adipose tissue | Sprague-Dawley rat | Down |
| Study M160 | Type2 | CUMS + CWD group vs. CUMS group | Adipose tissue | Sprague-Dawley rat | Up |
| Study M185 | Type1 | depressed group vs. control group | Serum | Human | Up |
| Study M186 | Type1 | depressed group vs. control group | Serum | Human | Down |
| Study M198 | Type1 | CUS group vs. control group | Midbrain | Long-Evans rat | Down |
| Study M198 | Type1 | CUS group vs. control group | Prefrontal cortex | Long-Evans rat | Down |
| Study M198 | Type1 | CUS group vs. control group | Plasma | Long-Evans rat | Up |
| Study M198 | Type1 | CUS group vs. control group | Hippocampus | Long-Evans rat | Down |
| Study M198 | Type1 | CUS group vs. control group | Hypothalamus | Long-Evans rat | Down |
| Study M198 | Type1 | CUS group vs. control group | Ventral striatum | Long-Evans rat | Down |
| Study M198 | Type1 | CUS group vs. control group | Amygdala | Long-Evans rat | Down |
| Study M202 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M206 | Type1 | WKY group vs. control group | Dorsal striatum | Wistar rat | Down |
| Study M206 | Type1 | bulbectomized group vs. sham group | Dorsal striatum | Wistar rat | Down |
| Study M206 | Type1 | WKY group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M206 | Type1 | bulbectomized group vs. sham group | Nucleus accumbens | Wistar rat | Up |
| Study M206 | Type1 | bulbectomized group vs. sham group | Prefrontal cortex | Wistar rat | Down |
| Study M206 | Type1 | bulbectomized group vs. sham group | Hippocampus | Wistar rat | Down |
| Study M476 | Type2 | URB597-treated CGI group vs. vehicle-treated CGI group | Hippocampus | Wistar rat | Up |
| Study M476 | Type2 | URB597-treated CGI group vs. vehicle-treated CGI group | Serum | Wistar rat | Up |
| Study M496 | Type2 | CMS + high dose of URB597 group vs. CMS group | Striatum | Wistar rat | Up |
| Study M496 | Type2 | CMS + high dose of URB597 group vs. CMS group | Thalamus | Wistar rat | Up |
| Study M496 | Type2 | CMS + high dose of URB597 group vs. CMS group | Midbrain | Wistar rat | Up |
| Study M498 | Type3 | chronic URB597 group vs. control group | Cerebellum | Wistar rat | Up |
| Study M498 | Type3 | chronic escitalopram group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | chronic tianeptine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | chronic URB597 group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | chronic URB597 group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | chronic escitalopram group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | chronic tianeptine group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | chronic imipramine group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | chronic imipramine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M498 | Type3 | acute N-acetylcysteine group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Frontal cortex | Wistar rat | Up |
| Study M498 | Type3 | chronic N-acetylcysteine group vs. control group | Dorsal striatum | Wistar rat | Up |
| Study M498 | Type3 | acute imipramine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M499 | Type3 | tranylcypromine group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M499 | Type3 | tranylcypromine group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M499 | Type3 | tranylcypromine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M500 | Type3 | single URB597 group vs. control group | Hippocampus | Wistar rat | Up |
| Study M500 | Type3 | repeated URB597 group vs. control group | Hippocampus | Wistar rat | Up |
| Study M500 | Type3 | single URB597 group vs. control group | Midbrain | Wistar rat | Up |
| Study M500 | Type3 | single URB597 group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M501 | Type3 | single ECS session group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M501 | Type3 | ten ECS sessions group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M501 | Type3 | single ECS session group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M503 | Type2 | SDS + URB694 group vs. SDS group | Striatum | Wistar Kyoto rat | Up |
| Study M503 | Type2 | SDS + URB694 group vs. SDS group | Plasma | Wistar Kyoto rat | Up |
| Study M503 | Type2 | SDS + URB694 group vs. SDS group | Prefrontal cortex | Wistar Kyoto rat | Up |
| Study M504 | Type1 | Dysbiotic group vs. control group | Duodenum | C57/BL6 mouse | Down |
| Study M504 | Type2 | Dysbiotic + probiotic group vs. Dysbiotic group | Jejunum | C57/BL6 mouse | Up |
| Study M505 | Type1 | WKY group vs. WIS group | Hippocampus | Wistar rat | Down |
| Study M505 | Type2 | WKY + URB597 vs. WKY + vehicle group | Frontal cortex | Wistar rat | Up |
| Study M505 | Type2 | WKY + URB597 vs. WKY + vehicle group | Hippocampus | Wistar rat | Up |
| Study M548 | Type1 | FSL group vs. FRL group | Plasma | Sprague-Dawley rat | Up |
| Study M548 | Type1 | FSL group vs. FRL group, right hippocampus | Hippocampus | Sprague-Dawley rat | Up |
| Study M548 | Type1 | FSL group vs. FRL group, left hippocampus | Hippocampus | Sprague-Dawley rat | Down |
| Study M557 | Type2 | MDD group, after vs. before prescribed moderate exercise | Serum | Human | Up |
| Study M598 | Type1 | MS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M697 | Type1 | social isolation group vs. control group | Hippocampus | Groningen rat | Down |
| Study M697 | Type2 | social isolation + URB694 group vs. social isolation group | Hippocampus | Groningen rat | Up |
| Study M705 | Type1 | maternal separation group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M709 | Type2 | EPA + DHA group, after vs. before group | Plasma | Human | Down |
| Study M709 | Type2 | EPA group, after vs. before group | Plasma | Human | Down |
| Study M709 | Type2 | DHA group, after vs. before group | Plasma | Human | Down |
| Study M717 | Type3 | citalopram group vs. control group, at week 4 | Frontal cortex | Wistar rat | Up |
| Study M717 | Type3 | citalopram group vs. control group, at week 4 | Amygdala | Wistar rat | Up |
| Study M717 | Type3 | nortriptyline group vs. control group, at week 4 | Frontal cortex | Wistar rat | Up |
| Study M717 | Type3 | nortriptyline group vs. control group, at week 4 | Hippocampus | Wistar rat | Up |
| Study M717 | Type3 | citalopram group vs. control group, at week 4 | Hippocampus | Wistar rat | Up |
| Study M763 | Type1 | grief group vs. control group | Serum | Human | Up |
| Study M811 | Type2 | CUMS + middle dose of dipyrone group vs. CUMS group | Amygdala | Balb/c mouse | Up |
| Study M811 | Type2 | CUMS + high dose of dipyrone group vs. CUMS group | Amygdala | Balb/c mouse | Up |
| Study M823 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M823 | Type2 | CUMS + albiflorin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M871 | Type1 | grief with high loneliness group vs. control group | Serum | Human | Up |
| Study M888 | Type2 | CUMS microbiota + L. plantarum Lp group vs. CUMS microbiota group | Hippocampus | C57BL/6J mouse | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M993 | Type1 | depression group vs. control group | Plasma | Human | Up |